Cogstate Limited (CGS) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Well, welcome everyone to Cogstate's Full Year Results for Financial Year 26. I'm pleased to introduce our presenters today, Brad O'Connor, Cogstate's CEO and Managing Director, Jaron Watson, our CFO, and Rachel Collar, our Executive Vice President of Clinical Trials. Before we get started, a reminder that this webinar is being recorded and all participants are in listen-only mode. We'll be opening for questions at the end and invite you to submit those questions using the chat function below. We'll try to get through as many of your questions in the allotted time and may aggregate similar questions. This webinar will be available later today on our Investor Centre. Over to you, Brad. Thank you, Rebecca. Today's presentation does include forward-looking statements and therefore I note our disclaimer stating this information in the presentation is general in nature and I encourage all investors to consider your own investment objectives and to review in detail our full year FY26 results that were lodged with the ASX earlier today. So look, I think FY26 is landmark year for Cogstate and delivered on our strategy diversification and expansion of our offering and that delivered not just record financial results but also an increase in the scale of the business all at the same time we're investing in technology and planning the next phase of the growth in our business and it's a really exciting time for everyone who's involved in the cogstate business from management to board to shareholders and i think we all fence feel that real sense of momentum that exists within the business at the moment As a management team, we feel that the strategies that we've put in place over probably more than the last five years are starting to really bear fruit. And that's reflected in our ...